文献速递中毒与环境急症复苏、休克与脓毒症

肌内注射纳洛酮1.6 mg后急性阿片戒断:一项院外前瞻性系列研究

Acute Opioid Withdrawal Following Intramuscular Administration of Naloxone 1.6 mg: A Prospective Out-Of-Hospital Series.
PubMed 文献 · Ann Emerg Med · 2022-04-29
一句话结论院外疑似阿片中毒致呼吸抑制成人单次肌内注射纳洛酮1.6 mg,严重激越发生率7%,97%逆转呼吸抑制。

该前瞻性研究纳入澳大利亚某州救护车机构救治的>15岁、因疑似阿片中毒出现呼吸抑制(呼吸频率<11次/分和/或室内空气氧饱和度<93%)而接受单次纳洛酮1.6 mg肌内注射的患者。2019年10月至2021年7月共197次就诊(171例患者),严重激越(Sedation Assessment Tool评分>1)发生14次(7%,95%CI 4%-12%),阿片戒断发生76次(39%,95%CI 32%-46%),最常见为心动过速(18%)、轻度激越/焦虑(18%)和高血压(14%)。3次就诊(1.5%)在给药后1小时内因严重激越接受化学镇静。单次1.6 mg纳洛酮逆转呼吸抑制192次(97%,95%CI 94%-99%)。作者结论认为严重激越不常见,且很少需要化学镇静。

要点

  • 院外成人疑似阿片中毒呼吸抑制,单次肌内注射纳洛酮1.6 mg后严重激越(Sedation Assessment Tool评分>1)发生率为7%(95%CI 4%-12%)。
  • 阿片戒断发生率为39%(95%CI 32%-46%),最常见为心动过速(18%)、轻度激越/焦虑(18%)和高血压(14%)。
  • 仅1.5%的就诊在纳洛酮给药后1小时内因严重激越接受化学镇静。
  • 单次1.6 mg肌内注射纳洛酮逆转呼吸抑制的比例为97%(95%CI 94%-99%)。

适用人群与场景

  • 澳大利亚某州救护车机构救治的成人(>15岁)患者。
  • 因疑似阿片中毒导致呼吸抑制(呼吸频率<11次/分和/或室内空气氧饱和度<93%)而接受单次纳洛酮1.6 mg肌内注射。

诊断标准与关键阈值

  • 呼吸抑制定义:呼吸频率<11次/分和/或室内空气氧饱和度<93%。
  • 严重激越定义:纳洛酮给药后1小时内Sedation Assessment Tool评分>1。
  • 急性阿片戒断定义:出现心动过速(脉率>100次/分)、高血压(收缩压>140 mm Hg)、呕吐、激越、癫痫发作、心肌梗死、心律失常或肺水肿。
  • 呼吸抑制逆转定义:呼吸频率>10次/分且氧饱和度>92%,或Glasgow Coma Scale评分15分。

处置流程与药物剂量

  • 对疑似阿片中毒所致呼吸抑制(呼吸频率<11次/分和/或室内空气氧饱和度<93%)的成人(>15岁)患者,给予单次纳洛酮1.6 mg肌内注射。

红旗征与不能漏的情况

  • 纳洛酮给药后1小时内出现严重激越(Sedation Assessment Tool评分>1),本研究中3次就诊(1.5%)因此接受化学镇静。
  • 急性阿片戒断表现:心动过速(脉率>100次/分)、高血压(收缩压>140 mm Hg)、呕吐、激越、癫痫发作、心肌梗死、心律失常或肺水肿。

研究设计与关键结果

  • 前瞻性研究,2019年10月至2021年7月共纳入197次就诊(171例患者),中位年龄41岁(范围18至80岁),男性119例(70%)。
  • 最常见阿片类药物为海洛因(131次[66%])、羟考酮(14次[7%])和吗啡(11次[6%])。
  • 严重激越发生14次(7%,95%CI 4%-12%)。
  • 阿片戒断发生76次(39%,95%CI 32%-46%),最常见为心动过速(18%)、轻度激越/焦虑(18%)和高血压(14%)。
  • 3次就诊(1.5%)在纳洛酮给药后1小时内因严重激越接受化学镇静。
  • 单次1.6 mg纳洛酮逆转呼吸抑制192次(97%,95%CI 94%-99%)。

证据类型、等级与局限

  • 证据类型:前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,肌内注射纳洛酮1.6 mg后严重激越不常见,且很少需要化学镇静。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Large doses of intramuscular (IM) naloxone are commonly used in out-of-hospital settings to reverse opioid toxicity; however, they are used less commonly in hospitals because of concerns about opioid withdrawal, particularly agitation. We aimed to determine the frequency of severe agitation following a single 1.6 mg IM naloxone dose.

METHODS: We undertook a prospective study of adult (>15 years) patients treated by an Australian state ambulance service with 1.6 mg IM administration of naloxone for respiratory depression (respiratory rate <11 breaths/min and/or oxygen saturation <93% in room air) caused by presumed opioid poisoning. The primary outcome was the proportion of presentations with severe agitation (Sedation Assessment Tool score >1) within 1 hour of naloxone administration. Secondary outcomes were the proportion of presentations with acute opioid withdrawal (tachycardia [pulse rate >100 beats/min], hypertension [systolic >140 mm Hg], vomiting, agitation, seizure, myocardial infarction, arrhythmia, or pulmonary edema), and reversal of respiratory depression (respiratory rate >10 breaths/min and saturation >92% or Glasgow Coma Scale score 15).

RESULTS: From October 2019 to July 2021, there were 197 presentations in 171 patients, with a median age of 41 years (range, 18 to 80 years); of the total patients, 119 were men (70%). The most common opioids were heroin (131 [66%]), oxycodone (14 [7%]), and morphine (11 [6%]). Severe agitation occurred in 14 (7% [95% confidence interval {CI} 4% to 12%]) presentations. Opioid withdrawal occurred in 76 presentations (39% [95% CI 32% to 46%]), most commonly in the form of tachycardia (18%), mild agitation/anxiety (18%) and hypertension (14%). Three presentations (1.5%) received chemical sedation for severe agitation within 1 hour of naloxone administration. A single 1.6 mg dose of naloxone reversed respiratory depression in 192 (97% [95% CI: 94% to 99%]) presentations.

CONCLUSION: Severe agitation was uncommon following the administration of 1.6 mg IM naloxone and rarely required chemical sedation.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Isoardi KZ, Parker L, Harris K, et al. Acute Opioid Withdrawal Following Intramuscular Administration of Naloxone 1.6 mg: A Prospective Out-Of-Hospital Series. Ann Emerg Med. 2022. PMID: 35491292. doi:10.1016/j.annemergmed.2022.03.004

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。